capillus hair loss

Capillus is Proud to Debut at the Medica 2017 World Forum for Medicine

Capillus is Proud to Debut at the Medica 2017 World Forum for Medicine

Capillus, LLC Capillus is making its inaugural appearance at the Medica 2017 World Forum for Medicine. Medica 2017 which is taking place this week in Dusseldorf, Germany runs from November 13th to November 16th, 2017.

Capillus is not only delighted to be a first-time exhibitor at Medica, but it is equally excited to showcase its complete line of laser therapy caps including the recently released CapillusRX™ which contains more lasers than any low-level laser therapy device in the market for home treatment of hair loss.

Its 312 diodes provide maximum simultaneous coverage of the scalp by any device for treatment of hereditary hair loss. It is available only through the company’s global physician network.

Medica is the world’s largest medical trade fair for medical technology, electro-medical equipment, laboratory equipment, diagnostics and pharmaceuticals. The fair is held annually and it is open to trade visitors only.

Capillus New Design of Laser Therapy Caps

Capillus’ Chief Executive Officer, Carlos Piña, along with Chief Operating Officer, Maria Piña, Director of International Sales, Fernando Bermudez, and Director of International Distribution, Lisa Weaver will be attending Medica 2017.

“Capillus’ goal, during Medica 2017, is to showcase our full-line of laser therapy caps as an effective method of treating pattern baldness in men and women,” said Carlos Piña, Capillus Chief Executive Officer, “we wish to broaden our reach and educate distributors in all fields of medicine on how our products can help prevent hair loss and promote hair regrowth.”

Capillus will be meeting with major distributors from around the world including Mexico, South Korea, Saudi Arabia, and the United Arab Emirates during the Medica 2017 World Forum for Medicine.

In addition to its CapillusRX™ available only through its physician network, Capillus currently offers three FDA-Cleared laser caps for direct sale via 1) Capillus82™, an economical and convenient device with 82 laser diodes, 2) Capillus202™, a powerful yet affordable device containing 202 laser diodes, as well as 3) CapillusPRO™, a professional-grade device with 272 laser diodes. Capillus laser therapy caps use Low Level Laser Therapy technology (LLLT), which is a non-invasive and chemical-free medical treatment for hair loss.

The Capillus laser therapy caps use a six-minute protocol which greatly reduces the time it takes to receive treatment. Capillus laser therapy caps are manufactured in the USA from foreign-source raw materials. The Capillus facility is ISO 13485 compliant, and it is located in Miami, Florida.

About Capillus, LLC 

Capillus, LLC offers prescription and over-the-counter hair regrowth products and medical devices for both men and women suffering from hair loss.

The Capillus premiere product lines include low-level laser therapy (LLLT) devices that are FDA-cleared and manufactured in the US under the highest-quality certification standard for the medical device industry (ISO13485). Capillus also offers additional non-prescription clinical hair products for hair and scalp health. Capillus products are available directly to the public for at-home use and also to their network of physicians for office use.

For more information visit



Published Clinical Study Shows Capillus Laser Therapy Safe and Effective at Treating Female Androgenetic Alopecia

Published Clinical Study Shows Capillus Laser Therapy “Safe and Effective” at Treating Female Androgenetic Alopecia

A peer-reviewed study authored by Dr. Shelly Friedman, D.O., F.A.O.C.D. and supported by Patricia Schnoor, BSBA, confirms that low-level laser therapy (LLLT) with Capillus® may play a considerable role in the treatment of androgenetic alopecia for females, given the impartial evidence illustrating favorable hair regrowth results.

The research was published in the June 2017 edition of Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery, encouraging familiarity of LLLT as a practical method of fighting hair loss at home within the greater medical community.

Dr. Friedman of the Scottsdale Institute for Cosmetic Dermatology is a board-certified hair restoration surgeon with nearly three decades of experience treating over 15,000 patients with hair loss.

Patricia Schnoor is the head of quality assurance and governmental affairs at Capillus, overseeing the assembly, testing and quality control for Capillus’ line of FDA-cleared at-home laser caps.

The study’s circulation is expected to pave access to new international markets, allowing more individuals to undergo laser therapy hair loss treatment by way of physician prescription or recommendation.

“Performing and publishing clinical research under the rigor of a prestigious journal is of critical importance for doctors prescribing under evidence based practice guidelines,” said Fernando Bermúdez, Director of International Distribution at Capillus. “Published data is also a reference for increasingly savvy consumers wanting to make an educated purchase decision before committing to a long-term treatment.”

The purpose of this randomized controlled trial was to outline the effects of photobiomodulation, or laser light, on the hair follicle and surrounding tissues in patients suffering from hair loss. The subjects consisted of 44 healthy females ages 18 to 60 years who were recruited at two separate board–approved treatment sites.

The Capillus272™ Pro was used in the study under the alias of a “handi-dome” laser device. Using the discreet dome insert with laser diodes operating at 650 nm, active participants receiving LLLT with the Capillus272 Pro™ showed a 51 percent mean increase in hair counts compared to patients who used a seemingly identical yet defunct device.

The researchers concluded that low-level laser treatment administered for 30 minutes every other day for 17 weeks is both safe and effective in treating androgenetic alopecia in healthy females between the ages of 18 to 60 with Fitzpatrick skin Types I to IV and Ludwig–Savin Baldness Scale I-2 to II-2 baldness patterns.

No side effects or adverse reactions were reported by any subject at any time during the study.

For more, view the published abstract on Dermatologic Surgery, June 2017 – Volume 43 – Edition 6.

About Capillus

Capillus proudly offers hair regrowth products and medical devices recommended by hair restoration physicians around the world for both men and women with hair loss.

Capillus’s premiere product lines include low level laser therapy (LLLT) devices that are FDA-Cleared and manufactured in the USA under the highest quality certification standard for the medical device industry (ISO13485).  Capillus272 Pro, Capillus 202, and Capillus82 are light-weight and battery-operated laser therapy caps for at-home hair loss treatment, used 30 minutes every other day and worn discreetly under a sports cap.

The Capillus272 OfficePro is for laser therapy sessions administered in salons and clinics for clients seeking introductory treatment.  Capillus laser therapy devices feature more lasers than any other FDA-Cleared clinical device on the market for non-presrciption sale. Capillus offers additional products for clinical hair therapy and scalp health as well as keratin hair fibers for temporary concealment of thin hair. Readers are invited to visit to learn more about Capillus hair regrowth products and laser therapy medical devices.